Business
Curasight Announces Successful Dosing of First Patient in Phase 1 trial with uTREAT® in Brain Cancer
Curasight A/S ("Curasight" or "the Company" – TICKER: CURAS) today announced the successful and safe dosing of the first patient in the Phase 1 trial using uTREAT in brain cancer (high grade gliomas). The news marks the initiation of the first clinical trial under the company's therapeutic platform uTREAT, investigating it as a potential treatment option for glioblastoma.
About this update from Curasight A/s
[{"type":"list","items":[{"val":[{"type":"text","content":"Phase 1 trial in aggressive brain cancer (Glioblastoma) is the first clinical trial of uTREAT® belonging to Curasight's treatment platform","length":142,"tagName":"p"}]},{"val":[{"type":"text","content":"No patient safety issues were reported ","length":38,"tagName":"p"}]},{"val":[{"type":"text","content":"The dosing marks a key milestone with Curasight now in clinical development with both its therapeutic (uTREAT®) and diagnostic (uTRACE®) platforms","length":146,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":326,"olType":false},{"type":"text","content":"COPENHAGEN, Denmark, Dec. 18, 2025 /PRNewswire/ -- Curasight A/S ("Curasight" or "the Company" – TICKER: CURAS) today announced the successful and safe dosing of the first patient in the Phase 1 trial using uTREAT in brain cancer (high grade gliomas). The news marks the initiation of the first clinical trial under the company's therapeutic platform uTREAT, investigating it as a potential treatment option for glioblastoma. ","length":449,"tagName":"p"},{"type":"text","content":"The start of the phase 1 study with uTREAT means that Curasight is now in the clinical phase with both parts of its theranostic platform aimed at improving treatment and diagnosis of certain cancers. The company's diagnostic platform uTRACE is currently in a Phase 2 trial for prostate cancer under the strategic partnership with Curium Inc.","length":345,"tagName":"p"},{"type":"text","content":""The dosing of the first patient with uTREAT in this Phase 1 trial marks an important step in the development of the therapeutic arm of our theranostic platform, making Curasight a clinical stage therapeutic company". Said Curasight's CEO Ulrich Krasilnikoff. "I very much look forward to seeing the data and would like to take this opportunity to thank the patient and doctors involved in this trial in supporting our efforts to develop uTREAT ". ","length":476,"tagName":"p"},{"type":"text","content":"About the Phase 1 trial with uTREAT in brain cancer","length":51,"tagName":"p"},{"type":"text","content":"The trial aims to investigate Curasight's uTREAT as a new type of targeted radiopharmaceutical therapy in glioblastoma patients. Participants in the trial are patients with newly diagnosed verified or suspec...